Maria E. Arcila, MD

Articles by Maria E. Arcila, MD

Dr. Arcila on Choosing Between Molecular Tests in Lung Cancer

July 31st 2021

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer

ByMaria E. Arcila, MD

November 10th 2014

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

Latest Updated Articles

Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer
Published: November 10th 2014 | Updated:

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD